Clinical therapeutic effectiveness of trimetazidine in the treatment of patients with dilated cardiomyopathy.

Objective To probe into the clinical therapeutic effectiveness of trimetazidine in the treatment of dilated cardiomyopathy(DCM) associated with moderate to severe chronic congestive heart failure(CHF).Methods Sixty patients with DCM associated with moderate to severe CHF were randomly divided into 2 groups:control group(n=29) and experimental group(n=31).Patients in control group were routinely treated with digitalis,diuretics,convertir enzyme inhibitor,β-receptor blocker etc..On the basis of the routine treatment,patients in experimental,group were received additionally 20 mg of trimetazidine PO,three times every day.The course of treatment lasted 8 weeks.The grade of cardiac function,left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVDd) and the serum level of Nt-pro brain natriuretic peptide(Nt-proBNP) were determined before and after 8 weeks after treatment in all groups.Results The grade of cardiac function in expenmental group was significantly improved after the trimetazidine treatment(P0.05).In group,the LVEF was dramatically increased,and the LVDd greatly reduced,and the serum level of Nt-proBNP significantly decreased after the treatment.However,the blood pressure and heart rate showed no apparent changes in patients treated with trimetazidine.Conclusion Trimetazidine was shown to have good therapeutic effects in the treatment of patients with DCM associated with CHF.